Dr Stanley Irwin Rekant, MD | |
777 S White Horse Pike, Suite A-2, Hammonton, NJ 08037-2029 | |
(609) 567-0030 | |
(609) 567-0716 |
Full Name | Dr Stanley Irwin Rekant |
---|---|
Gender | Male |
Speciality | Dermatology |
Location | 777 S White Horse Pike, Hammonton, New Jersey |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1154314052 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207N00000X | Dermatology | MA02729500 (New Jersey) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Stanley Irwin Rekant, MD 777 S White Horse Pike, Suite A-2, Hammonton, NJ 08037-2029 Ph: (609) 567-0030 | Dr Stanley Irwin Rekant, MD 777 S White Horse Pike, Suite A-2, Hammonton, NJ 08037-2029 Ph: (609) 567-0030 |
News Archive
According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.
Keith Houlihan, president and Chief Executive Officer of Sanomedics International Holdings Inc., today announced the launch of Sanomedics Development Corporation, to be led by Abhishek Shrivastava, Chief Technology Officer.
A recently discovered facet of the breast cancer susceptibility gene BRCA1 reveals a mechanism linking mutation of BRCA1 to formation of large blood vessels needed to support cancer progression.
The survival rates for older women with breast cancer lag behind younger women diagnosed with the disease, indicating that the elder population may be missing out on improvements in treatment and detection, according to new research from the University of Texas MD Anderson Cancer Center.
The binding of a SARS-CoV-2 virus surface protein spike - a projection from the spherical virus particle - to the human cell surface protein ACE2 is the first step to infection that may lead to COVID-19 disease.
› Verified 5 days ago